In short
Primary hyperaldosteronism is a surprisingly common but often overlooked condition that affects blood pressure. Understanding when and how to test for it can make the difference between years of difficult-to-control high blood pressure and targeted, effective treatment that protects the heart, kidneys, and other vital organs.
Key points
- Primary hyperaldosteronism affects 5-10% of people with high blood pressure, making it far more common than most doctors recognize—it's the leading cause of curable high blood pressure
- The simple aldosterone-to-renin ratio blood test can screen for the condition, yet fewer than 5% of people who should be tested actually receive screening
- Normal potassium levels don't rule out primary hyperaldosteronism—most people with the condition have potassium in the normal range
- Excess aldosterone is toxic to organs and increases the risk of heart attack, stroke, kidney failure, and death by up to tenfold compared to regular high blood pressure
- Adrenal venous sampling, though technically challenging, is the gold standard for determining whether one or both adrenal glands are affected—information that's crucial for treatment planning
- Many common blood pressure medications interfere with diagnostic testing, so you may need to temporarily stop certain medications under medical supervision to get accurate results
- With proper diagnosis and treatment—whether surgery or targeted medications—most people with primary hyperaldosteronism have excellent outcomes and significantly reduced health risks
- If your blood pressure requires three or more medications, started before age 30, or has been difficult to control, you should specifically ask your doctor about screening for primary hyperaldosteronism
Introduction: Who Should Be Tested and When
Primary hyperaldosteronism used to be thought of as a rare disorder, but today medical experts recognize it as one of the most common causes of secondary hypertension, which means high blood pressure caused by an identifiable underlying condition. Between 5% and 10% of all adults with high blood pressure have this condition, making it far more widespread than previously believed. In people whose blood pressure remains stubbornly high despite taking multiple medications, the numbers are even more striking—some studies suggest that up to 25% of people with medication-resistant hypertension may have primary hyperaldosteronism.
The challenge with primary hyperaldosteronism is that it often doesn't announce itself with obvious symptoms. While the classic picture described decades ago included both high blood pressure and low potassium levels in the blood, most people with this condition today have normal potassium levels, making it much harder for doctors to recognize. This is one reason why the condition remains significantly underdiagnosed—studies show that fewer than 5% of people who should be screened for primary hyperaldosteronism actually receive testing.
Certain groups of people are at higher risk and should definitely be considered for testing. If you have high blood pressure that started before age 30, or if your blood pressure requires three or more medications to manage, you should ask your doctor about screening for primary hyperaldosteronism. People who have been found to have an adrenal tumor (a growth on one of the small glands that sit atop the kidneys) during imaging tests done for other reasons should also be evaluated. Additionally, if you have low potassium levels alongside high blood pressure, this combination is a red flag that warrants further investigation.
It's also important to consider testing if you have a family history of early-onset stroke or if you've been diagnosed with resistant hypertension—meaning your blood pressure stays elevated despite taking multiple blood pressure medications. Some experts even suggest that all people with high blood pressure should be screened for this condition, given how common it is and how much harm it can cause if left untreated.
Diagnostic Methods: How Primary Hyperaldosteronism Is Identified
The diagnosis of primary hyperaldosteronism follows a systematic approach that typically involves several steps. The process begins with screening tests and, if those are positive, moves on to confirmatory tests and imaging studies to determine the exact cause and location of the problem.
Initial Screening Blood Tests
The first step in diagnosing primary hyperaldosteronism involves measuring specific hormones in your blood. Healthcare providers use blood tests to check the levels of aldosterone (the hormone that's overproduced in this condition) and renin (an enzyme made by the kidneys that normally regulates aldosterone production). These tests are usually done in the morning because hormone levels can vary throughout the day.
The key measurement is called the aldosterone-to-renin ratio, sometimes abbreviated as ARR. In primary hyperaldosteronism, the aldosterone level is high while the renin level is low or completely undetectable. When the ratio of aldosterone to renin exceeds 20:1, it strongly suggests that the adrenal glands are producing too much aldosterone independently of the normal control mechanisms. This screening test is simple and readily available, which is why experts emphasize it should be used much more widely than it currently is.
At the same time, doctors will also check your blood for levels of electrolytes, particularly sodium and potassium. While many people with primary hyperaldosteronism have normal potassium levels, some do have low potassium (hypokalemia), which can provide additional clues about the diagnosis.
One important thing to know is that certain medications can interfere with these hormone measurements and give inaccurate results. Blood pressure medications are especially likely to affect the test. Your doctor will review all your medications and may ask you to stop taking certain ones for four to six weeks before testing to ensure accurate results. This can be challenging if you need those medications to control your blood pressure, so it requires careful medical supervision.
Confirmatory Testing
If the initial screening blood test suggests primary hyperaldosteronism, doctors usually recommend additional tests to confirm the diagnosis. These confirmatory tests are designed to see whether aldosterone production can be suppressed—something that should happen normally but doesn't in people with primary hyperaldosteronism.
One common confirmatory test is called salt loading. This involves either eating a high-salt diet for several days or receiving salt through an intravenous line, followed by blood and urine tests to see how your body responds. In healthy people, extra salt should signal the adrenal glands to reduce aldosterone production. But in someone with primary hyperaldosteronism, aldosterone levels remain elevated despite the extra salt.
Another confirmatory test is the captopril suppression test. Captopril is a medication used to treat high blood pressure. This test measures how your aldosterone and renin levels respond after taking a dose of captopril. The results help confirm whether you truly have primary hyperaldosteronism or whether your initial screening test was falsely positive.
Some centers also use a test that measures aldosterone levels in urine collected over a 24-hour period while the person eats a high-salt diet. If aldosterone levels in the urine remain high despite the salt intake, this confirms the diagnosis.
Imaging Studies to Find the Source
Once the diagnosis of primary hyperaldosteronism is confirmed through blood and urine tests, the next step is to figure out exactly what's causing the problem. This matters because the treatment approach differs depending on whether one adrenal gland is affected or both are involved.
The most common initial imaging test is a CT scan (computed tomography) of the abdomen. This creates detailed cross-sectional images of the adrenal glands and can show whether there's a tumor or growth present. The two most common causes of primary hyperaldosteronism are an aldosterone-producing adenoma (a benign tumor on one adrenal gland) and bilateral adrenal hyperplasia (when both glands are overactive).
However, CT scans alone cannot always distinguish between these two causes with certainty. An adrenal gland might look normal on a CT scan even when it's producing too much aldosterone, or a scan might show a small growth that isn't actually the source of the problem. This is where a specialized test called adrenal venous sampling (AVS) becomes important.
Adrenal Venous Sampling: The Gold Standard
Adrenal venous sampling is considered the most accurate way to determine whether one or both adrenal glands are responsible for excess aldosterone production. During this procedure, a skilled radiologist uses a thin tube called a catheter to take blood samples directly from the veins draining each adrenal gland. The aldosterone levels in these samples are then measured to see which gland (or both) is producing too much hormone.
This test requires significant expertise and is typically performed at specialized centers. Not all hospitals have radiologists trained in this technique. While it's more invasive than other tests, adrenal venous sampling provides critical information that helps doctors decide whether surgery might cure the condition or whether medication will be needed.
Diagnostics for Clinical Trial Qualification
When patients with primary hyperaldosteronism are being considered for enrollment in clinical trials, the diagnostic criteria often follow standardized protocols to ensure consistent patient selection across different research sites. Clinical trials typically require documentation of the diagnosis through the same basic screening and confirmatory tests used in regular clinical practice.
The aldosterone-to-renin ratio measured in morning blood samples serves as the standard screening criterion for most clinical trials studying primary hyperaldosteronism. A ratio greater than 20:1 is commonly used as the threshold for considering further evaluation. Many research protocols also specify that the absolute aldosterone level must be above a certain value, not just that the ratio is elevated, to ensure that participants truly have autonomous aldosterone production.
Clinical trials often require confirmatory testing to ensure accurate diagnosis before enrollment. This might include one or more of the suppression tests described earlier—salt loading tests, captopril suppression tests, or measurement of 24-hour urinary aldosterone excretion on a high-salt diet. These confirmatory steps help exclude people who might have had false-positive screening tests, ensuring that study results reflect the true effects of interventions on people who genuinely have the condition.
For trials comparing surgical versus medical treatment, or for studies specifically targeting unilateral disease, protocols typically mandate adrenal venous sampling to definitively establish which adrenal gland is responsible for aldosterone excess. This is crucial because the presence of unilateral versus bilateral disease fundamentally affects treatment decisions and outcomes.
Some clinical trials also include detailed characterization of the underlying subtype of primary hyperaldosteronism. This might involve genetic testing to identify familial forms of the condition, particularly the inherited types classified as familial hyperaldosteronism types I, II, or III. These genetic evaluations help researchers understand whether certain treatments work better for specific subtypes of the condition.
Prognosis and Survival Rate
Prognosis
The outlook for people with primary hyperaldosteronism depends largely on how quickly the condition is diagnosed and how effectively it is treated. When diagnosed early and treated appropriately, most people have an excellent prognosis. For those with unilateral disease who undergo surgical removal of the affected adrenal gland, many experience either complete cure or substantial improvement in their blood pressure control. Even when blood pressure doesn't completely normalize after surgery, patients typically need fewer medications to manage it compared to before the operation.
For people with bilateral adrenal hyperplasia who are treated with medications called mineralocorticoid receptor antagonists, along with other blood pressure medications as needed, the prognosis is also generally good when treatment is properly managed. These medications can effectively control blood pressure and help prevent the serious complications associated with untreated primary hyperaldosteronism.
However, the prognosis is significantly worse when primary hyperaldosteronism goes undiagnosed or untreated. Compared to people with regular high blood pressure at the same blood pressure level, those with untreated primary hyperaldosteronism face dramatically higher risks. The excess aldosterone itself—independent of blood pressure—damages organs over time. This leads to increased risk of heart attack, stroke, atrial fibrillation (an irregular heart rhythm), heart failure, kidney damage, and even early death. In fact, the risk of these cardiovascular complications can be up to ten times higher in people with primary hyperaldosteronism compared to those with similar blood pressure from other causes.
The extent of organ damage that has already occurred by the time of diagnosis also affects prognosis. People who have already developed chronic kidney disease, heart problems, or have had previous strokes face ongoing health challenges even with treatment. This underscores the importance of screening at-risk individuals before serious complications develop. Studies have shown that when primary hyperaldosteronism is treated, whether through surgery or appropriate medications, patients' cardiovascular risk decreases and overall health outcomes improve significantly.
Survival Rate
Specific long-term survival statistics for primary hyperaldosteronism are not extensively detailed in standard medical literature, partly because the condition has historically been underdiagnosed and its impact has not been tracked separately from other forms of hypertension. However, research has established that untreated primary hyperaldosteronism is associated with significantly increased mortality risk compared to essential (regular) hypertension.
What is well-documented is that primary hyperaldosteronism substantially increases the risk of life-threatening events. People with this condition who don't receive appropriate treatment face elevated rates of fatal strokes, heart attacks, and sudden cardiac events compared to people with similar blood pressure levels from other causes. The toxic effects of excess aldosterone on the cardiovascular system and kidneys contribute directly to this increased mortality risk.
On a more positive note, studies show that proper treatment—whether through surgery for unilateral disease or with mineralocorticoid receptor antagonists for bilateral disease—can dramatically reduce these risks and improve long-term outcomes. Patients who receive targeted treatment for primary hyperaldosteronism have mortality rates that approach those of people with regular high blood pressure, representing a substantial improvement over the natural course of untreated disease. This highlights why early diagnosis and appropriate treatment are so crucial for preserving both quality of life and longevity.
